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Introduction {#sec005}
============

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology, characterized by peripheral polyarthritis. Approximately 1% of the general population worldwide is affected by RA, with an increasing prevalence in the older population \[[@pone.0205651.ref001]\]. As the aging population continues to grow, the mean age of RA patients in clinical studies has continuously increased for several decades. In Korea, the population aged 65 years and over is expected to account for 25% of the general population by 2030 \[[@pone.0205651.ref002]\]. Among patients with RA, the proportion of elderly patients is rapidly growing.

Because age is one of the major determinants in clinical decision-making, there are distinct considerations for treatment strategies and clinical outcomes for elderly patients with RA. Elderly patients frequently have other medical conditions that restrict tight control of RA activity. The current consensus on RA treatment emphasizes treat-to-target strategy for better clinical outcomes \[[@pone.0205651.ref003]\]. The therapeutic target is disease remission, and if this is unattainable, then the target is maintaining a low disease activity. However, it is difficult to determine the optimal treatment in elderly patients with comorbidities. Although disease-modifying anti-rheumatic drugs (DMARDs) are beneficial to reach the target, elderly patients are at increased risk of developing side effects of DMARDs owing to organ dysfunction. Moreover, immune system aging makes elderly patients more susceptible to infection during immunosuppressive therapy \[[@pone.0205651.ref004]\]. Thus, physicians often hesitate to use intensive treatment for elderly patients with RA.

Currently, there has been increasing attention on elderly patients with RA among rheumatologists. Recent studies have demonstrated different features in patients that developed RA at an older age. Elderly onset RA has a higher proportion of male patients, and it develops more abruptly \[[@pone.0205651.ref005]--[@pone.0205651.ref007]\]. In terms of clinical outcomes, patients with elderly onset RA tend to have severe functional disabilities and poor life quality compared with younger onset RA patients \[[@pone.0205651.ref005],[@pone.0205651.ref008],[@pone.0205651.ref009]\]. However, there are still limited data concerning the clinical features and outcomes of elderly patients with RA. As previous studies have mainly focused on the onset age of RA rather than the present age of patients, it is difficult to identify the practical impact of age on disease control. Furthermore, most clinical trials exclude patients with risk factors such as old age and comorbid disease for safety issues. To understand the characteristics of elderly patients with RA in real clinical practice, the clinical profiles and outcome measures in elderly patients should be reviewed using a large patient registry.

In this study, we investigated the clinical features and disease control status in elderly patients with RA using a nationwide registry. We also analyzed the clinical factors affecting insufficient control of RA activity.

Methods {#sec006}
=======

Patient population {#sec007}
------------------

The Korean College of Rheumatology Biologics Registry for RA (KOBIO-RA) is a nationwide, multi-center cohort that aims to evaluate the clinical outcomes and adverse effects of treatment with biologics in Korean patients with RA. Patients with RA were recruited from 38 hospitals in South Korea since 2012. The enrolled patients were evaluated by rheumatologists, and an informed consent was obtained from all subjects.

The registry consists of two arms: one arm comprises patients starting or switching to a new biologic agent (biologics group), and the other arm comprises patients treated with conventional synthetic DMARDs (control group). Biologic agents comprised rituximab, abatacept, tocilizumab, and tumor necrosis factor inhibitors, including etanercept, infliximab, adalimumab, golimumab, and certolizumab. If a patient in the control group began biologic agent therapy, this patient was reclassified into the biologics group. In Korea, the health care reimbursement system permits biologic agent use in RA patients who have an inadequate response to more than one conventional DMARDs. Further, it is recommended that patients are prescribed with one DMARD, mainly methotrexate (MTX), concurrently with a biologic agent.

The present study is based on cross-sectional data of patient characteristics at enrollment in KOBIO-RA between 2012 and 2014. For comparison between non-elderly and elderly patients, all patients were classified by age at enrollment. Patients aged 65 years or over were categorized as elderly patients, and others were considered non-elderly patients. Names and hospital identification numbers were removed to ensure patient confidentiality. Ethical approval of KOBIO-RA was obtained by all of the institutional review boards of 38 participating institutions, including Yonsei University College of Medicine (4-2013-0075) and the Catholic University College of Medicine (KC12OIMI0675).

Clinical profiles {#sec008}
-----------------

An electrical case report form was employed via the Internet to gather patient data \[[@pone.0205651.ref010]\]. Data included demographics, previous or current use of medications, comorbidities, and extra-articular manifestations. The clinical information was mainly obtained from health questionnaires and interviews with patients.

The investigators of each institution collected laboratory and radiologic findings. Laboratory tests included complete blood count, blood chemistry, and autoantibodies, such as rheumatoid factor and anti-cyclic citrullinated peptide antibody (ACPA). Structural damage, including bony erosion and joint space narrowing, was evaluated on plain radiographs of the hands and feet.

To guarantee the quality of the data, the investigators participated in a workshop supervised by the central task force of the Korean College of Rheumatology. Evaluation was performed at inclusion, initiation, or change of biologic agent, and at every follow-up.

Comorbidities {#sec009}
-------------

To evaluate the clinical impact of comorbidities, the presence of comorbid disease was assessed in the entire study population. Patients were asked about previous diagnoses of other diseases. Additionally, accessible medical records or medications lists were verified by the investigators at each institution. To detect pulmonary comorbidities, chest imaging and pulmonary function tests were reviewed. Chronic obstructive pulmonary disease and restrictive lung disease were determined by abnormalities in pulmonary function tests. Interstitial lung disease, combined with RA, was confined to relevant findings in imaging studies. Chronic kidney disease was defined as estimated glomerular filtration rate less than 60 ml/min calculated using the Modification of Diet in Renal Disease Study equation. Comorbidity information was summarized into numeric scores using the Charlson Comorbidity Index (CCI) \[[@pone.0205651.ref011]\] and the Elixhauser's Comorbidity Measure (ECM) \[[@pone.0205651.ref012]\] to compare the effect of multiple comorbid conditions.

Assessment of disease activity {#sec010}
------------------------------

The disease activity of all patients was evaluated using validated composite measures at every evaluation. Trained investigators at each institution performed joint assessments. Disease activity was presented with various indices, including disease activity score in 28 joints (DAS28) using erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) (DAS28-ESR and DAS28-CRP, respectively), simplified disease activity index (SDAI), and clinical disease activity index (CDAI). Based on the American College of Rheumatology-European League against Rheumatism criteria, the current disease status was categorized into remission, or high, moderate, or low disease activity \[[@pone.0205651.ref013]\].

The functional capacity of patients with RA was determined using a specialized tool, the Routine Assessment of Patient Index Data 3 (RAPID3) \[[@pone.0205651.ref014]\]. All patients filled in the questionnaire at every data collection point.

Statistical analysis {#sec011}
--------------------

Characteristics of non-elderly and elderly patients in KOBIO-RA were compared using Student's *t*-test and the chi-square test. A multivariate logistic regression model was used to determine the independent risk factors for high disease activity of RA. The clinical variables with *P* ≤ 0.10 in univariate analysis were included in the multivariate regression model. *P*-values \<0.05 were considered significant. All statistical analyses were performed using SAS 9.1 software (SAS Institute, Inc., Cary, NC, USA).

Results {#sec012}
=======

Patient characteristics {#sec013}
-----------------------

The baseline characteristics of patients in KOBIO-RA are presented in [Table 1](#pone.0205651.t001){ref-type="table"}. Patients had mean age of 54.2 years, and 86.1% of patients were women. Of 1,227 patients at inclusion, 244 patients were classified as elderly patients (age ≥ 65 years). The proportion of men was higher and disease duration was longer in elderly patients compared to non-elderly patients (*P* = 0.012 and *P* \< 0.001, respectively). Seropositivity for rheumatoid factor and ACPA, and the presence of radiographic erosion was comparable between non-elderly and elderly patients with RA. Extra-articular manifestations of RA were also comparable in both groups, although interstitial lung disease was more common in elderly patients (*P* = 0.025).

10.1371/journal.pone.0205651.t001

###### Baseline characteristics of RA patients at enrollment of KOBIO-RA.
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  ----------------------------------------------------------------------------------------------------------------------------------------------
                                                                      Total\             Non-elderly patients\   Elderly\            *P*-value
                                                                      (n = 1227)         (age \< 65 years)\      patients\           
                                                                                         (n = 983)               (age ≥ 65 years)\   
                                                                                                                 (n = 244)           
  --------------------- --------------------------------------------- ------------------ ----------------------- ------------------- -----------
  Demographics          Age (years), mean ± SD                        54.2 ± 12.4        50.2 ± 10.4             70.3 ± 4.2          \<0.001

                        Sex (women), n (%)                            1057 (86.1)        859 (87.4)              198 (81.1)          0.012

                        Duration of education (years), mean ± SD      11.4 ± 3.7         12.1 ± 3.3              8.8 ± 4.0           \<0.001

                        Smoking                                                                                                      0.468

                        Current smoker, n (%)                         91 (7.4)           73 (7.4)                18 (7.4)            

                        Ex-smoker, n (%)                              85 (6.9)           63 (6.4)                22 (9.0)            

  RA-related features   Age at RA diagnosis, mean ± SD                45.4 ± 14.5        42.1 ± 12.7             58.4 ± 14.2         \<0.001

                        Duration of disease (years), mean ± SD        7.9 ± 7.4          7.4 ± 7.0               9.9 ± 8.7           \<0.001

                        Seropositivity, n (%)                         1095/1173 (93.4)   877 (93.2)              218 (94.0)          0.675

                        Rheumatoid factor-positive, n (%)             1001/1190 (84.1)   794 (83.3)              207 (87.3)          0.129

                        ACPA-positive, n (%)                          844/1003 (84.1)    687 (84.0)              157 (84.9)          0.767

                        Erosive arthritis, n (%)                      481/870 (55.3)     390 (54.9)              91 (57.2)           0.585

  Extra-articular       Rheumatoid nodule, n (%)                      25 (2.1)           17 (1.7)                8 (3.4)             0.162

  manifestations        Interstitial lung disease, n (%)              19 (1.6)           11 (1.1)                8 (3.4)             0.025

                        Pleuritis, n (%)                              4 (0.3)            3 (0.3)                 1 (0.4)             0.538

                        Glomerulonephritis, n (%)                     3 (0.2)            1 (0.1)                 2 (0.8)             0.068

                        Scleritis, n (%)                              2 (0.2)            1 (0.1)                 1 (0.4)             0.311

                        Cutaneous vasculitis, n (%)                   2 (0.2)            2 (0.2)                 0 (0.0)             0.437

                        Secondary Sjögren's syndrome, n (%)           28 (2.3)           20 (2.1)                8 (3.4)             0.270

  Comorbidities         Hypertension, n (%)                           318 (25.9)         198 (20.1)              120 (49.2)          \<0.001

                        Diabetes, n (%)                               104 (8.5)          50 (5.1)                54 (22.1)           \<0.001

                        Cerebrovascular disease, n (%)                9 (0.7)            3 (0.3)                 6 (2.5)             \<0.001

                        Ischemic heart disease, n (%)                 17 (1.4)           7 (0.7)                 10 (4.1)            \<0.001

                        Congestive heart failure, n (%)               3 (0.2)            0 (0.0)                 3 (1.2)             \<0.001

                        Peripheral vascular disease, n (%)            3 (0.2)            2 (0.2)                 1 (0.4)             0.559

                        COPD, n (%)                                   15 (1.2)           6 (0.6)                 9 (3.7)             \<0.001

                        Restrictive lung disease, n (%)               22 (1.8)           12 (1.2)                10 (4.1)            0.002

                        Chronic kidney disease, n (%)                 51 (4.2)           20 (2.0)                31 (12.7)           \<0.001

                        Liver disease, n (%)                          47 (3.8)           42 (4.3)                5 (2.0)             0.105

                        Peptic ulcer disease, n (%)                   48 (3.9)           31 (3.2)                17 (7.0)            0.006

                        Depression, n (%)                             26 (2.1)           21 (2.1)                5 (2.0)             0.933

                        Hematologic malignancies, n (%)               2 (0.2)            2 (0.2)                 0 (0.0)             0.481

                        Solid tumor, n (%)                            13 (1.1)           9 (0.9)                 4 (1.6)             0.323

                        Metastatic tumor, n (%)                       1 (0.1)            1 (0.1)                 0 (0.0)             0.618

                        Charlson Comorbidity Index, mean ± SD         1.39 ± 0.95        1.26 ± 0.79             1.88 ± 1.33         \<0.001

                        Elixhauser's Comorbidity Measure, mean ± SD   1.83 ± 0.94        1.70 ± 0.85             2.38 ± 1.06         \<0.001

  Medications           Synthetic DMARDs                                                                                             

                        Methotrexate, n (%)                           1043 (85.0)        852 (86.7)              191 (78.3)          0.004

                        Leflunomide, n (%)                            318 (25.9)         248 (25.2)              70 (28.7)           0.397

                        Sulfasalazine, n (%)                          143 (11.7)         112 (11.4)              31 (12.7)           0.649

                        Hydroxychloroquine, n (%)                     318 (25.9)         260 (26.4)              58 (23.8)           0.563

                        Tacrolimus, n (%)                             149 (12.1)         117 (11.9)              32 (13.1)           0.668

                        Dual DMARD therapy, n (%)                     585 (48.4)         466 (48.1)              119 (49.8)          0.638

                        Triple DMARD therapy, n (%)                   94 (7.7)           79 (8.0)                15 (6.1)            0.487

                        Quadruple DMARD therapy, n (%)                8 (0.7)            6 (0.6)                 2 (0.8)             0.727

                        Corticosteroids, n (%)                        971 (79.1)         780 (79.3)              191 (78.3)          0.713

                        Dose of corticosteroids (mg/day), mean ± SD   4.1 ± 3.8          3.9 ± 3.3               4.1 ± 3.9           0.357

                        Biologic agents, n (%)                        200 (16.3)         162 (16.5)              38 (15.6)           0.732

                        Tumor necrosis factor inhibitors, n (%)       170 (13.9)         136 (13.8)              34 (13.9)           0.968

                        Rituximab, n (%)                              10 (0.8)           9 (0.9)                 1 (0.4)             0.432

                        Abatacept, n (%)                              15 (1.2)           12 (1.2)                3 (1.2)             0.991

                        Tocilizumab, n (%)                            5 (0.4)            5 (0.5)                 0 (0.0)             0.264
  ----------------------------------------------------------------------------------------------------------------------------------------------

SD, standard deviation; RA, rheumatoid arthritis; ACPA, anti-cyclic citrullinated peptide antibody; COPD, chronic obstructive pulmonary disease; DMARD, disease modifying anti-rheumatic drug.

The two groups had a significant difference in comorbid conditions, including hypertension, diabetes, cardiovascular disease, pulmonary disease, renal insufficiency, and peptic ulcer. The prevalence of these diseases was higher in elderly patients, as expected. Accordingly, comorbidity indices (CCI and ECM) were elevated in the elderly group. Comparison of current medications revealed a less common use of MTX in elderly patients (78.3% in the elderly group and 86.5% in the non-elderly group, *P* = 0.004). Other medications, including synthetic conventional DMARDs, corticosteroids, and biologic agents, were similarly prescribed in both groups. The frequency of combination therapy with more than one DMARD was not significantly different between non-elderly and elderly patients.

Disease activity {#sec014}
----------------

As shown in [Table 2](#pone.0205651.t002){ref-type="table"}, disease activity in all included patients was evaluated with various measures at inclusion. Among acute phase reactants, ESR was higher in elderly patients. However, the CRP level was not significantly different between the two groups.

10.1371/journal.pone.0205651.t002

###### Composite measures of disease activity in KOBIO-RA patients.
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  ----------------------------------------------------------------------------------------------------------------------------------------
                                                                    Total\         Non-elderly patients\   Elderly\            *P*-value
                                                                    (n = 1227)     (age \< 65 years)\      patients\           
                                                                                   (n = 983)               (age ≥ 65 years)\   
                                                                                                           (n = 244)           
  ------------------ ---------------------------------------------- -------------- ----------------------- ------------------- -----------
  Disease activity   ESR (mm/hr), mean ± SEM                        41.9 ± 0.8     40.6 ± 0.9              47.2 ± 2.0          0.002

                     CRP (mg/dl), mean ± SEM                        1.70 ± 0.08    1.66 ± 0.09             1.88 ± 0.16         0.231

                     Swollen joint count 28, mean ± SEM             5.0 ± 0.2      5.0 ± 0.2               5.4 ± 0.4           0.378

                     Tender joint count 28, mean ± SEM              6.7 ± 0.2      6.4 ± 0.2               7.9 ±0.6            0.026

                     Patient global assessment, mean ± SEM          5.3 ± 0.1      5.2 ± 0.1               5.6 ± 0.2           0.047

                     Physician global assessment, mean ± SEM        4.6 ± 0.1      4.6 ± 0.1               4.6 ± 0.2           0.994

                     DAS28-ESR, mean ± SEM                          4.64 ± 0.05    4.58 ± 0.05             4.89 ± 0.12         0.013

                     DAS28-CRP, mean ± SEM                          3.95 ± 0.05    3.90 ± 0.05             4.16 ± 0.12         0.045

                     SDAI, mean ± SEM                               21.40 ± 0.44   20.82 ± 0.47            23.75 ± 1.09        0.014

                     CDAI, mean ± SEM                               19.6 ± 0.4     19.2 ± 0.4              21.5 ± 1.0          0.036

                     State of disease activity based on DAS28-CRP                                                              0.035

                     Remission, n (%)                               338 (27.5)     273 (27.8)              65 (26.6)           

                     Low disease activity, n (%)                    112 (9.1)      91 (9.3)                21 (8.6)            

                     Moderate disease activity, n (%)               445 (36.3)     371 (37.7)              74 (30.3)           

                     High disease activity, n (%)                   315 (25.7)     237 (24.1)              78 (32.0)           

  Function           RAPID3, mean ± SD                              12.31 ± 6.82   12.00 ± 6.72            13.55 ± 7.09        0.002
  ----------------------------------------------------------------------------------------------------------------------------------------

SEM, standard error of mean; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS-28, disease activity score in 28 joints; SDAI, simplified disease activity index; CDAI, clinical disease activity index; RAPID3, routine assessment of patient index data 3.

Elderly patients had more tender joints but comparably swollen joints to non-elderly patients. There was a discrepancy in the perception of disease activity by patients and physicians, which was worse according to the patients' assessment. Although the global assessment by physicians did not differ significantly in both groups, elderly patients perceived their disease more severely than non-elderly patients.

The evaluation of the disease activity based on clinical and laboratory parameters revealed a higher disease activity in elderly patients compared to non-elderly patients. The scores of all activity indices were significantly higher in the elderly group. Most of the included patients (62.0%) had moderate to high disease activity despite treatment because the biologics group of KOBIO-RA consisted of patients with an inadequate response to conventional DMARDs or prior biologics. Of note, more patients in the elderly group were classified as having high disease activity compared to the non-elderly group (24.1% *vs* 32.0% according to DAS28-CRP) ([Fig 1](#pone.0205651.g001){ref-type="fig"}). Functional impairment and pain evaluated by RAPID 3 were more severe in elderly patients, and this finding was consistent with the result that elderly patients showed higher disease activity.

![Classification of disease activity in KOBIO-RA patients.\
Current rheumatoid arthritis (RA) activity in KOBIO-RA was determined by multiple validated composite measures of disease activity including joint counts: disease activity score in 28 joints using C-reactive protein (DAS28-CRP) or erythrocyte sedimentation rate (DAS28-ESR); simplified disease activity index (SDAI); and clinical disease activity index (CDAI). According to the American College of Rheumatology-European League against Rheumatism criteria, disease activity was classified into remission or low, moderate, or high disease activity.](pone.0205651.g001){#pone.0205651.g001}

Risk factors for high disease activity {#sec015}
--------------------------------------

Because the difference in disease activity of elderly and non-elderly patients was primarily high disease activity, the association between clinical profiles and high disease activity was investigated ([Table 3](#pone.0205651.t003){ref-type="table"}). As ESR is influenced by age, disease activity was classified based on DAS28-CRP. For the entire study population, old age, elderly onset of RA, and longer disease duration were related to high disease activity in univariate analysis. The disease activity of RA was also affected by education level, comorbidity, and MTX use. Male sex and presence of interstitial lung disease had no significant impact on disease activity. Multivariate analysis of significant factors revealed that longstanding RA over 10 years, presence of comorbid disease, and no use of MTX were independent risk factors for high disease activity in KOBIO-RA. When the disease activity was separately evaluated in elderly and non-elderly patients, these risk factors affected disease activity in a similar pattern ([Fig 2](#pone.0205651.g002){ref-type="fig"}). The comorbidity indices had linear correlations with DAS28-ESR and DAS28-CRP (all *P* \< 0.001).

![Assessment of disease activity according to the risk factors.\
Disease activity in the presence or absence of risk factors (**A**. non-use of MTX; **B**. disease duration over 10 years; **C**. presence of comorbidity) was evaluated using DAS28-CRP in elderly and non-elderly patients, respectively. The distribution of remission, and low, moderate, and high disease activity showed a similar pattern in the entire study population, the elderly group, and the non-elderly group.](pone.0205651.g002){#pone.0205651.g002}

10.1371/journal.pone.0205651.t003

###### Risk factors for high disease activity in KOBIO-RA patients.
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                                                     Univariate                       Multivariate           
  -------------------------------------------------- ---------------------- --------- ---------------------- ---------
  Old age (≥ 65 years)                               1.512 (1.111--2.057)   0.008                            
  Male                                               1.046 (0.724--1.512)   0.811                            
  Elderly onset of RA (≥ 60 years)                   1.479 (1.056--2.073)   0.023                            
  Longer duration of disease (≥ 10 years)            1.593 (1.215--2.089)   0.001     1.618 (1.201--2.180)   0.002
  Lower education level (≤ 12 years)                 1.356 (1.011--1.819)   0.042                            
  Presence of ILD                                    1.017 (0.363--2.847)   0.974                            
  Presence of comorbid conditions (ECM ≥ 2 points)   1.940 (1.481--2.541)   \<0.001   1.722 (1.297--2.285)   \<0.001
  No use of methotrexate                             1.568 (1.096--2.242)   0.014     1.503 (1.042--2.170)   0.029

OR, odds ratio; RA, rheumatoid arthritis; ILD, interstitial lung disease; ECM, Elixhauser's Comorbidity Measure; CI, confidence interval.

Because comorbidities were closely associated with high disease activity of RA, the impact of each comorbid disease was analyzed. No comorbidities, except diabetes, showed any significant association with high disease activity in KOBIO-RA. Diabetes had a marginal effect on the disease activity of RA, after adjustment with other covariates ([Table 4](#pone.0205651.t004){ref-type="table"}).

10.1371/journal.pone.0205651.t004

###### Comorbid conditions associated with high disease activity in KOBIO-RA patients.
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                             Univariate             After adjustment[\*](#t004fn001){ref-type="table-fn"}                          
  -------------------------- ---------------------- ------------------------------------------------------- ---------------------- -------
  Hypertension               0.940 (0.700--1.263)   0.682                                                                          
  Diabetes                   1.752 (1.148--2.673)   0.009                                                   1.549 (0.997--2.409)   0.052
  Cerebrovascular disease    0.353 (0.044--2.834)   0.327                                                                          
  Ischemic heart disease     0.946 (0.303--2.956)   0.924                                                                          
  Cardiac arrhythmia         0.947 (0.190--4.715)   0.947                                                                          
  Hypothyroidism             1.035 (0.527--2.029)   0.921                                                                          
  COPD                       1.912 (0.675--5.414)   0.223                                                                          
  Restrictive lung disease   1.640 (0.681--3.947)   0.270                                                                          
  Chronic kidney disease     0.918 (0.473--1.784)   0.918                                                                          
  Liver disease              1.394 (0.742--2.617)   0.302                                                                          
  Peptic ulcer disease       1.491 (0.804--2.766)   0.205                                                                          

\*Adjusted for age, sex, disease duration, and methotrexate treatment.

OR, odds ratio; COPD, chronic obstructive pulmonary disease; CI, confidence interval.

Discussion {#sec016}
==========

In the present study, elderly RA patients showed higher disease activity at enrollment of KOBIO-RA, compared to non-elderly patients. Various composite measures showed a higher proportion of high disease activity in elderly patients. However, age was not an independent risk factor for high disease activity of RA in entire study population. Patients with high disease activity had longstanding RA and were less frequently treated with MTX. Comorbidities were more common in elderly patients, and the presence of comorbidities was closely linked with high disease activity in RA.

Earlier research has shown that elderly patients with RA undergo less aggressive treatment. Age affected the treatment pattern, especially the use of conventional and biologic DMARDs \[[@pone.0205651.ref015]--[@pone.0205651.ref018]\]. In contrast, another study suggested similar use of DMARD therapy \[[@pone.0205651.ref019]\]. In the present study, the use of biologic agents or combination DMARD therapy was not significantly different between elderly and non-elderly patients with RA. The prescription of medications was comparable in both groups, except for MTX. All current guidelines recommend MTX as an anchor drug that should be started as soon as possible after diagnosing RA \[[@pone.0205651.ref020]--[@pone.0205651.ref022]\]. Treatment with MTX is known to significantly improve clinical outcomes in RA patients. However, the use of MTX is limited in patients with impaired kidney, lung, and liver function. Patients at risk of severe infection also have difficulties in taking MTX. Physicians tend to be reluctant to prescribe MTX for elderly patients with comorbidities and immunosenescence, resulting in unfavorable outcomes in elderly patients with RA \[[@pone.0205651.ref015],[@pone.0205651.ref016]\].

In line with these findings, comorbidity was an independent risk factor for uncontrolled disease activity in the whole study population. Comorbidity was previously known to have an independent association with clinical measures, such as the CDAI and the Health Assessment Questionnaire \[[@pone.0205651.ref023],[@pone.0205651.ref024]\]. We also found that the presence of comorbid disease has a significant correlation with disease activity indices, including DAS28. The safety concerns and contraindications for DMARDs in patients with comorbidities restrict tight control of disease activity. Moreover, earlier studies suggested decreased adherence to medications in RA patients with comorbid disease \[[@pone.0205651.ref025]\]. Diabetes was associated with non-adherence to treatment \[[@pone.0205651.ref026]\], supporting the current observation that patients with diabetes tend to have active RA. Because comorbid conditions affect both patients and health providers in the management of RA, adjustment of outcome measures by comorbidity would be required \[[@pone.0205651.ref027]\].

Although this study showed higher disease activity in elderly patients, the evaluation of disease activity of elderly patients with RA should be interpreted carefully. Importantly, the difference between elderly and non-elderly patients was mainly determined by subjective measures, rather than objective measures. Elderly patients with RA had worse outcomes in tender joint counts and patient global assessment compared to non-elderly patients, whereas swollen joint counts and physician global assessment were comparable. In general, the aging population is more susceptible to pain measured by the visual analogue scale and global assessment \[[@pone.0205651.ref028]\]. Additionally, ESR, an important acute phase reactant, is influenced by age, as well as inflammation \[[@pone.0205651.ref029]\]. To compensate for these limitations, we used various validated composite measures of disease activity that include joint assessment or not. All measures showed a similar pattern that revealed high disease activity in elderly patients with RA.

Interestingly, the proportion of remission and low disease activity were not significantly different between elderly and non-elderly patients. Although the primary target for treatment of RA is to reach a state of clinical remission, other treatment goal than remission should be chosen according to presence of comorbidity, and patient factors such as aging, with consideration of the safety aspect \[[@pone.0205651.ref003]\]. The therapeutic target can be generally adapted to reach remission or low disease activity. Based on this general principle, treatment goal attainment was comparable in elderly and non-elderly patients. However, structural destruction and functional disability can progress in proportion to disease activity. Thus, RA activity should be maintained as low as possible, even though the therapeutic goal is not reached.

The present study has several limitations. First, there was a selection bias affecting the disease activity of the entire study population. The biologics group, accounting for more than half of patients enrolled in KOBIO-RA, was comprised of patients with an inadequate response to prior treatment. At enrollment, these patients had moderate to high disease activity. Thus, the patients in KOBIO-RA had more active RA compared to all patients with RA. Actually, the mean DAS28 and the proportion of patients with moderate to high disease activity were higher in KOBIO-RA compared to other RA registries in Korea \[[@pone.0205651.ref030],[@pone.0205651.ref031]\]. Secondly, this study was based on cross-sectional data, and the response to RA treatment was not evaluated. Additional analysis from longitudinal data is required to investigate treatment outcomes in elderly patients with RA. Nevertheless, KOBIO-RA provides a better understanding of the nationwide characteristics of patients with RA in Korea.

In conclusion, elderly patients with RA had higher disease activity compared with non-elderly patients at enrollment of Korean nationwide biologics registry. High disease activity was associated with longer disease duration, limited use of MTX, and presence of comorbidities, rather than age itself. Patient characteristics need to be considered in the treatment of RA, especially in elderly patients at increased risk of high disease activity.
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RA

:   rheumatoid arthritis

DMARDs

:   disease modifying anti-rheumatic drugs

KOBIO-RA

:   Korean College of Rheumatology Biologics Registry for Rheumatoid Arthritis

MTX

:   methotrexate

ACPA

:   anti-cyclic citrullinated peptide antibody

CCI

:   Charlson Comorbidity Index

ECM

:   Elixhauser's Comorbidity Measure

DAS28

:   disease activity score in 28 joints

ESR

:   erythrocyte sedimentation rate

CRP

:   C-reactive protein

SDAI

:   simplified disease activity index

CDAI

:   clinical disease activity index (CDAI)

RAPID3

:   routine assessment of patient index data 3

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
